Neurofilaments as biomarkers in neurological disorders - towards clinical application.

Journal

Nature reviews. Neurology
ISSN: 1759-4766
Titre abrégé: Nat Rev Neurol
Pays: England
ID NLM: 101500072

Informations de publication

Date de publication:
12 Apr 2024
Historique:
accepted: 15 03 2024
medline: 13 4 2024
pubmed: 13 4 2024
entrez: 12 4 2024
Statut: aheadofprint

Résumé

Neurofilament proteins have been validated as specific body fluid biomarkers of neuro-axonal injury. The advent of highly sensitive analytical platforms that enable reliable quantification of neurofilaments in blood samples and simplify longitudinal follow-up has paved the way for the development of neurofilaments as a biomarker in clinical practice. Potential applications include assessment of disease activity, monitoring of treatment responses, and determining prognosis in many acute and chronic neurological disorders as well as their use as an outcome measure in trials of novel therapies. Progress has now moved the measurement of neurofilaments to the doorstep of routine clinical practice for the evaluation of individuals. In this Review, we first outline current knowledge on the structure and function of neurofilaments. We then discuss analytical and statistical approaches and challenges in determining neurofilament levels in different clinical contexts and assess the implications of neurofilament light chain (NfL) levels in normal ageing and the confounding factors that need to be considered when interpreting NfL measures. In addition, we summarize the current value and potential clinical applications of neurofilaments as a biomarker of neuro-axonal damage in a range of neurological disorders, including multiple sclerosis, Alzheimer disease, frontotemporal dementia, amyotrophic lateral sclerosis, stroke and cerebrovascular disease, traumatic brain injury, and Parkinson disease. We also consider the steps needed to complete the translation of neurofilaments from the laboratory to the management of neurological diseases in clinical practice.

Identifiants

DOI: 10.1038/s41582-024-00955-x PMID: 38609644
pubmed: 38609644
doi: 10.1038/s41582-024-00955-x
pii: 10.1038/s41582-024-00955-x
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. Springer Nature Limited.

Références

Khalil, M. et al. Neurofilaments as biomarkers in neurological disorders. Nat. Rev. Neurol. 14, 577–589 (2018).
pubmed: 30171200 doi: 10.1038/s41582-018-0058-z
Petzold, A. The 2022 Lady Estelle Wolfson lectureship on neurofilaments. J. Neurochem. 163, 179–219 (2022).
pubmed: 35950263 pmcid: 9826399 doi: 10.1111/jnc.15682
Norgren, N., Karlsson, J.-E., Rosengren, L. & Stigbrand, T. Monoclonal antibodies selective for low molecular weight neurofilaments. Hybrid. Hybridomics 21, 53–59 (2002).
pubmed: 11991817 doi: 10.1089/15368590252917647
Disanto, G. et al. Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann. Neurol. 81, 857–870 (2017).
pubmed: 28512753 pmcid: 5519945 doi: 10.1002/ana.24954
Gisslén, M. et al. Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine 3, 135–140 (2016).
pubmed: 26870824 doi: 10.1016/j.ebiom.2015.11.036
Spitzenberger, F. et al. Laboratory-developed tests: design of a regulatory strategy in compliance with the international state-of-the-art and the regulation (EU) 2017/746 (EU IVDR [In Vitro Diagnostic Medical Device Regulation]). Ther. Innov. Regul. Sci. 56, 47–64 (2022).
pubmed: 34291407 doi: 10.1007/s43441-021-00323-7
Hauser, S. L. et al. Ofatumumab versus teriflunomide in multiple sclerosis. N. Engl. J. Med. 383, 546–557 (2020).
pubmed: 32757523 doi: 10.1056/NEJMoa1917246
Tabrizi, S. J. et al. Targeting huntingtin expression in patients with Huntington’s disease. N. Engl. J. Med. 380, 2307–2316 (2019).
pubmed: 31059641 doi: 10.1056/NEJMoa1900907
Miller, T. M. et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N. Engl. J. Med. 387, 1099–1110 (2022).
pubmed: 36129998 doi: 10.1056/NEJMoa2204705
Mullard, A. NfL makes regulatory debut as neurodegenerative disease biomarker. Nat. Rev. Drug Discov. 22, 431–434 (2023).
pubmed: 37198334 doi: 10.1038/d41573-023-00083-z
Biogen. FDA Grants Accelerated Approval for QALSODY
Leptak, C. & Kozauer, N. Letter of Support to the International Progressive Multiple Sclerosis Alliance. U.S. Food & Drug Administration https://www.fda.gov/media/149608/download (2021).
Cooke, E. Letter of Support of Neurofilament Light in Childhood Neurological Diseases. European Medicines Agency https://www.ema.europa.eu/en/documents/other/letter-support-neurofilament-light-childhood-neurological-diseases_en.pdf (2022).
Koini, M. et al. Factors influencing serum neurofilament light chain levels in normal aging. Aging 13, 25729–25738 (2021).
pubmed: 34923481 pmcid: 8751593 doi: 10.18632/aging.203790
Fitzgerald, K. C. et al. Contributors to serum NFL levels in people without neurologic disease. Ann. Neurol. 92, 688–698 (2022).
pubmed: 35730070 pmcid: 9489658 doi: 10.1002/ana.26446
Benkert, P. et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol. 21, 246–257 (2022).
pubmed: 35182510 doi: 10.1016/S1474-4422(22)00009-6
Shaw, G. et al. Uman-type neurofilament light antibodies are effective reagents for the imaging of neurodegeneration. Brain Commun. 5, fcad067 (2023).
pubmed: 37091583 pmcid: 10120172 doi: 10.1093/braincomms/fcad067
Gafson, A. R. et al. Neurofilaments: neurobiological foundations for biomarker applications. Brain 143, 1975–1998 (2020).
pubmed: 32408345 pmcid: 7363489 doi: 10.1093/brain/awaa098
Andreasson, U. et al. Assessing the commutability of candidate reference materials for the harmonization of neurofilament light measurements in blood. Clin. Chem. Lab. Med. 61, 1245–1254 (2023).
pubmed: 36709509 doi: 10.1515/cclm-2022-1181
Eldirany, S. A., Lomakin, I. B., Ho, M. & Bunick, C. G. Recent insight into intermediate filament structure. Curr. Opin. Cell Biol. 68, 132–143 (2021).
pubmed: 33190098 doi: 10.1016/j.ceb.2020.10.001
Ghosh, K., Huihui, J., Phillips, M. & Haider, A. Rules of physical mathematics govern intrinsically disordered proteins. Annu. Rev. Biophys. 51, 355–376 (2022).
pubmed: 35119946 pmcid: 9190209 doi: 10.1146/annurev-biophys-120221-095357
Janmey, P. A., Leterrier, J.-F. & Herrmann, H. Assembly and structure of neurofilaments. Curr. Opin. Colloid Interface Sci. 8, 40–47 (2003).
doi: 10.1016/S1359-0294(03)00010-4
Trimpin, S. et al. Identification of endogenous phosphorylation sites of bovine medium and low molecular weight neurofilament proteins by tandem mass spectrometry. Biochemistry 43, 2091–2105 (2004).
pubmed: 14967049 doi: 10.1021/bi030196q
Petzold, A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J. Neurol. Sci. 233, 183–198 (2005).
pubmed: 15896809 doi: 10.1016/j.jns.2005.03.015
Rebelo, A. P. et al. Cryptic amyloidogenic elements in the 3’ UTRs of neurofilament genes trigger axonal neuropathy. Am. J. Hum. Genet. 98, 597–614 (2016).
pubmed: 27040688 pmcid: 4833435 doi: 10.1016/j.ajhg.2016.02.022
Murray, K. A. et al. Identifying amyloid-related diseases by mapping mutations in low-complexity protein domains to pathologies. Nat. Struct. Mol. Biol. 29, 529–536 (2022).
pubmed: 35637421 pmcid: 9205782 doi: 10.1038/s41594-022-00774-y
Xiao, S., McLean, J. & Robertson, J. Neuronal intermediate filaments and ALS: a new look at an old question. Biochim. Biophys. Acta Mol. Basis Dis. 1762, 1001–1012 (2006).
doi: 10.1016/j.bbadis.2006.09.003
Petzold, A. et al. Protein aggregate formation permits millennium-old brain preservation. J. R. Soc. Interface 17, 20190775 (2020).
pubmed: 31910770 pmcid: 7014809 doi: 10.1098/rsif.2019.0775
Briot, J., Simon, M. & Méchin, M.-C. Deimination, intermediate filaments and associated proteins. Int. J. Mol. Sci. 21, 8746 (2020).
pubmed: 33228136 pmcid: 7699402 doi: 10.3390/ijms21228746
Cloos, P. A. C. & Christgau, S. Post-translational modifications of proteins: implications for aging, antigen recognition, and autoimmunity. Biogerontology 5, 139–158 (2004).
pubmed: 15190184 doi: 10.1023/B:BGEN.0000031152.31352.8b
Yuzwa, S. A. et al. Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat. Chem. Biol. 8, 393–399 (2012).
pubmed: 22366723 doi: 10.1038/nchembio.797
Zucchi, E. et al. A motor neuron strategy to save time and energy in neurodegeneration: adaptive protein stoichiometry. J. Neurochem. 146, 631–641 (2018).
pubmed: 29959860 pmcid: 6175430 doi: 10.1111/jnc.14542
Jones, J. B. & Safinya, C. R. Interplay between liquid crystalline and isotropic gels in self-assembled neurofilament networks. Biophys. J. 95, 823–835 (2008).
pubmed: 18583309 pmcid: 2440473 doi: 10.1529/biophysj.107.127415
Lasek, R. J., Phillips, L., Katz, M. J. & Autilio-Gambetti, L. Function and evolution of neurofilament proteins. Ann. N. Y. Acad. Sci. 455, 462–478 (1985).
pubmed: 3936386 doi: 10.1111/j.1749-6632.1985.tb50429.x
Monaco, S., Autilio-Gambetti, L., Lasek, R. J., Katz, M. J. & Gambetti, P. Experimental increase of neurofilament transport rate: decreases in neurofilament number and in axon diameter. J. Neuropathol. Exp. Neurol. 48, 23–32 (1989).
pubmed: 2908896 doi: 10.1097/00005072-198901000-00003
Lasek, R. J., Oblinger, M. M. & Drake, P. F. Molecular biology of neuronal geometry: expression of neurofilament genes influences axonal diameter. Cold Spring Harb. Symp. Quant. Biol. 48, 731–744 (1983).
pubmed: 6202455 doi: 10.1101/SQB.1983.048.01.076
Balaratnasingam, C. et al. Axonal transport and cytoskeletal changes in the laminar regions after elevated intraocular pressure. Invest. Ophthalmol. Vis. Sci. 48, 3632–3644 (2007).
pubmed: 17652733 doi: 10.1167/iovs.06-1002
Vial, J. D. The early changes in the axoplasm during Wallerian degeneration. J. Biophys. Biochem. Cytol. 4, 551–555 (1958).
pubmed: 13587548 pmcid: 2224545 doi: 10.1083/jcb.4.5.551
Lasek, R. J. Bidirectional transport of radioactively labelled axoplasmic components. Nature 216, 1212–1214 (1967).
pubmed: 6076067 doi: 10.1038/2161212a0
Nixon, R. A. & Logvinenko, K. B. Multiple fates of newly synthesized neurofilament proteins: evidence for a stationary neurofilament network distributed nonuniformly along axons of retinal ganglion cell neurons. J. Cell Biol. 102, 647–659 (1986).
pubmed: 2418034 doi: 10.1083/jcb.102.2.647
Mutalik, S. P. & Ghose, A. Axonal cytomechanics in neuronal development. J. Biosci. 45, 64 (2020).
pubmed: 32385223 doi: 10.1007/s12038-020-00029-2
Gentil, B. J. et al. Normal role of the low-molecular-weight neurofilament protein in mitochondrial dynamics and disruption in Charcot-Marie-Tooth disease. FASEB J. 26, 1194–1203 (2012).
pubmed: 22155564 doi: 10.1096/fj.11-196345
Wagner, O. I. et al. Mechanisms of mitochondria-neurofilament interactions. J. Neurosci. 23, 9046–9058 (2003).
pubmed: 14534238 pmcid: 6740819 doi: 10.1523/JNEUROSCI.23-27-09046.2003
Zhu, P.-P. et al. Transverse endoplasmic reticulum expansion in hereditary spastic paraplegia corticospinal axons. Hum. Mol. Genet. 31, 2779–2795 (2022).
pubmed: 35348668 pmcid: 9402237 doi: 10.1093/hmg/ddac072
Dashiell, S. M., Tanner, S. L., Pant, H. C. & Quarles, R. H. Myelin-associated glycoprotein modulates expression and phosphorylation of neuronal cytoskeletal elements and their associated kinases. J. Neurochem. 81, 1263–1272 (2002).
pubmed: 12068074 doi: 10.1046/j.1471-4159.2002.00927.x
Petzold, A. et al. In vivo monitoring of neuronal loss in traumatic brain injury: a microdialysis study. Brain 134, 464–483 (2011).
pubmed: 21278408 pmcid: 3030768 doi: 10.1093/brain/awq360
Altmann, P. et al. Seven day pre-analytical stability of serum and plasma neurofilament light chain. Sci. Rep. 11, 11034 (2021).
pubmed: 34040118 pmcid: 8154890 doi: 10.1038/s41598-021-90639-z
Brureau, A. et al. NF-L in cerebrospinal fluid and serum is a biomarker of neuronal damage in an inducible mouse model of neurodegeneration. Neurobiol. Dis. 104, 73–84 (2017).
pubmed: 28392472 doi: 10.1016/j.nbd.2017.04.007
Geisler, N. & Weber, K. Comparison of the proteins of two immunologically distinct intermediate-sized filaments by amino acid sequence analysis: desmin and vimentin. Proc. Natl Acad. Sci. USA 78, 4120–4123 (1981).
pubmed: 6945574 pmcid: 319739 doi: 10.1073/pnas.78.7.4120
Budelier, M. M. et al. A map of neurofilament light chain species in brain and cerebrospinal fluid and alterations in Alzheimer’s disease. Brain Commun. 4, fcac045 (2022).
pubmed: 35415607 pmcid: 8994116 doi: 10.1093/braincomms/fcac045
Woltsche, N. et al. Neurofilament light chain: a new marker for neuronal decay in the anterior chamber fluid of patients with glaucoma. Br. J. Ophthalmol. 107, 1432–1437 (2022).
pubmed: 35750478 doi: 10.1136/bjo-2021-320828
Plog, B. A. et al. Biomarkers of traumatic injury are transported from brain to blood via the glymphatic system. J. Neurosci. 35, 518–526 (2015).
pubmed: 25589747 pmcid: 4293408 doi: 10.1523/JNEUROSCI.3742-14.2015
Engel, S. et al. Elevated neurofilament light chain CSF/serum ratio indicates impaired CSF outflow in idiopathic intracranial hypertension. Fluids Barriers CNS 20, 3 (2023).
pubmed: 36631830 pmcid: 9832777 doi: 10.1186/s12987-022-00403-2
Hier, D. B. et al. Blood biomarkers for mild traumatic brain injury: a selective review of unresolved issues. Biomark. Res. 9, 70 (2021).
pubmed: 34530937 pmcid: 8447604 doi: 10.1186/s40364-021-00325-5
Azizi, S. et al. A kinetic model for blood biomarker levels after mild traumatic brain injury. Front. Neurol. 12, 668606 (2021).
pubmed: 34295300 pmcid: 8289906 doi: 10.3389/fneur.2021.668606
Thelin, E. P. et al. Serial sampling of serum protein biomarkers for monitoring human traumatic brain injury dynamics: a systematic review. Front. Neurol. 8, 300 (2017).
pubmed: 28717351 pmcid: 5494601 doi: 10.3389/fneur.2017.00300
Karlsson, M. et al. A single-cell type transcriptomics map of human tissues. Sci. Adv. 7, eabh2169 (2021).
pubmed: 34321199 pmcid: 8318366 doi: 10.1126/sciadv.abh2169
Keddie, S. et al. Peripherin is a biomarker of axonal damage in peripheral nervous system disease. Brain 146, 4562–4573 (2023).
pubmed: 37435933 pmcid: 10629771 doi: 10.1093/brain/awad234
Yuan, A. et al. Peripherin is a subunit of peripheral nerve neurofilaments: implications for differential vulnerability of CNS and peripheral nervous system axons. J. Neurosci. 32, 8501–8508 (2012).
pubmed: 22723690 pmcid: 3405552 doi: 10.1523/JNEUROSCI.1081-12.2012
Petzold, A., Keir, G., Green, A. J. E., Giovannoni, G. & Thompson, E. J. A specific ELISA for measuring neurofilament heavy chain phosphoforms. J. Immunol. Methods 278, 179–190 (2003).
pubmed: 12957406 doi: 10.1016/S0022-1759(03)00189-3
Gaiottino, J. et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS ONE 8, e75091 (2013).
pubmed: 24073237 pmcid: 3779219 doi: 10.1371/journal.pone.0075091
Rissin, D. M. & Walt, D. R. Digital concentration readout of single enzyme molecules using femtoliter arrays and Poisson statistics. Nano Lett. 6, 520–523 (2006).
pubmed: 16522055 doi: 10.1021/nl060227d
Wilson, D. H. et al. The simoa HD-1 analyzer: a novel fully automated digital immunoassay analyzer with single-molecule sensitivity and multiplexing. J. Lab. Autom. 21, 533–547 (2016).
pubmed: 26077162 doi: 10.1177/2211068215589580
Rissin, D. M. et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat. Biotechnol. 28, 595–599 (2010).
pubmed: 20495550 pmcid: 2919230 doi: 10.1038/nbt.1641
Petzold, A. et al. Neurofilament ELISA validation. J. Immunol. Methods 352, 23–31 (2010).
pubmed: 19857497 doi: 10.1016/j.jim.2009.09.014
Kuhle, J. et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin. Chem. Lab. Med. 54, 1655–1661 (2016).
pubmed: 27071153 doi: 10.1515/cclm-2015-1195
Brousse, M. et al. Serum neurofilament light chain cut-off definition for clinical diagnosis and prognosis of amyotrophic lateral sclerosis. Eur. J. Neurol. 30, 1919–1927 (2023).
pubmed: 37029777 doi: 10.1111/ene.15813
Lee, S. et al. Development of a highly sensitive neurofilament light chain assay on an automated immunoassay platform. Front. Neurol. 13, 935382 (2022).
pubmed: 35959400 pmcid: 9359312 doi: 10.3389/fneur.2022.935382
Yuan, A. & Nixon, R. A. Neurofilament proteins as biomarkers to monitor neurological diseases and the efficacy of therapies. Front. Neurosci. 15, 689938 (2021).
pubmed: 34646114 pmcid: 8503617 doi: 10.3389/fnins.2021.689938
Harp, C. et al. Development of an age-adjusted model for blood neurofilament light chain. Ann. Clin. Transl. Neurol. 9, 444–453 (2022).
pubmed: 35229997 pmcid: 8994974 doi: 10.1002/acn3.51524
Khalil, M. et al. Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat. Commun. 11, 812 (2020).
pubmed: 32041951 pmcid: 7010701 doi: 10.1038/s41467-020-14612-6
Yilmaz, A. et al. Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. Expert Rev. Mol. Diagn. 17, 761–770 (2017).
pubmed: 28598205 doi: 10.1080/14737159.2017.1341313
Bridel, C. et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol. 76, 1035–1048 (2019).
pubmed: 31206160 pmcid: 6580449 doi: 10.1001/jamaneurol.2019.1534
Idland, A.-V. et al. CSF neurofilament light levels predict hippocampal atrophy in cognitively healthy older adults. Neurobiol. Aging 49, 138–144 (2017).
pubmed: 27794264 doi: 10.1016/j.neurobiolaging.2016.09.012
Reiber, H. Flow rate of cerebrospinal fluid (CSF) — a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J. Neurol. Sci. 122, 189–203 (1994).
pubmed: 8021703 doi: 10.1016/0022-510X(94)90298-4
Mattsson, N., Andreasson, U., Zetterberg, H. & Blennow, K., Alzheimer’s Disease Neuroimaging Initiative.Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 74, 557–566 (2017).
pubmed: 28346578 pmcid: 5822204 doi: 10.1001/jamaneurol.2016.6117
Manouchehrinia, A. et al. Confounding effect of blood volume and body mass index on blood neurofilament light chain levels. Ann. Clin. Transl. Neurol. 7, 139–143 (2020).
pubmed: 31893563 pmcid: 6952306 doi: 10.1002/acn3.50972
Simrén, J. et al. Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5–90 years. Brain Commun. 4, fcac174 (2022).
pubmed: 35865350 pmcid: 9297091 doi: 10.1093/braincomms/fcac174
Tang, R. et al. Association of neurofilament light chain with renal function: mechanisms and clinical implications. Alzheimers Res. Ther. 14, 189 (2022).
pubmed: 36527130 pmcid: 9756450 doi: 10.1186/s13195-022-01134-0
Akamine, S. et al. Renal function is associated with blood neurofilament light chain level in older adults. Sci. Rep. 10, 20350 (2020).
pubmed: 33230211 pmcid: 7683708 doi: 10.1038/s41598-020-76990-7
Kosa, P. et al. Enhancing the clinical value of serum neurofilament light chain measurement. JCI Insight 7, e161415 (2022).
pubmed: 35737460 pmcid: 9462467 doi: 10.1172/jci.insight.161415
Simonsen, A. H. et al. Neurofilament light chain levels in serum among a large mixed memory clinic cohort: confounders and diagnostic usefulness. Alzheimers Dement. 15, e12512 (2023).
Sjölin, K. et al. Serum neurofilament light chain in patients with atrial fibrillation. J. Am. Heart Assoc. 11, e025910 (2022).
pubmed: 35861814 pmcid: 9707825 doi: 10.1161/JAHA.122.025910
Polymeris, A. A. et al. Serum neurofilament light in atrial fibrillation: clinical, neuroimaging and cognitive correlates. Brain Commun. 2, fcaa166 (2020).
pubmed: 33381755 pmcid: 7753055 doi: 10.1093/braincomms/fcaa166
Li, Y. et al. Neurofilament light chain is a promising biomarker in alcohol dependence. Front. Psychiatry 12, 754969 (2021).
pubmed: 34867542 pmcid: 8637455 doi: 10.3389/fpsyt.2021.754969
Sareban, M. et al. Serum neurofilament level increases after ascent to 4559 m but is not related to acute mountain sickness. Eur. J. Neurol. 28, 1004–1008 (2021).
pubmed: 33095952 doi: 10.1111/ene.14606
Sönksen, S.-E. et al. Brain structure and neurocognitive function in two professional mountaineers during 35 days of severe normobaric hypoxia. Eur. J. Neurol. 29, 3112–3116 (2022).
pubmed: 35726171 doi: 10.1111/ene.15470
Isung, J. et al. Differential effects on blood and cerebrospinal fluid immune protein markers and kynurenine pathway metabolites from aerobic physical exercise in healthy subjects. Sci. Rep. 11, 1669 (2021).
pubmed: 33462306 pmcid: 7814004 doi: 10.1038/s41598-021-81306-4
Joisten, N. et al. Exercise diminishes plasma neurofilament light chain and reroutes the kynurenine pathway in multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 8, e982 (2021).
pubmed: 33782190 pmcid: 8054957 doi: 10.1212/NXI.0000000000000982
Bazarian, J. J. et al. Effects of physical exertion on early changes in blood-based brain biomarkers: implications for the acute point of care diagnosis of concussion. J. Neurotrauma 40, 693–705 (2023).
pubmed: 36200628 pmcid: 10061333 doi: 10.1089/neu.2022.0267
Kuhle, J. et al. Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS. Mult. Scler. 28, 573–582 (2022).
pubmed: 34378446 doi: 10.1177/13524585211032348
Sormani, M. P. et al. Blood neurofilament light as a potential endpoint in phase 2 studies in MS. Ann. Clin. Transl. Neurol. 6, 1081–1089 (2019).
pubmed: 31211172 pmcid: 6562031 doi: 10.1002/acn3.795
Leppert, D. et al. Blood neurofilament light in progressive multiple sclerosis: post hoc analysis of 2 randomized controlled trials. Neurology 98, e2120–e2131 (2022).
pubmed: 35379762 pmcid: 10263182 doi: 10.1212/WNL.0000000000200258
Vermunt, L. et al. Age‐ and disease‐specific reference values for neurofilament light presented in an online interactive support interface. Ann. Clin. Transl. Neurol. 9, 1832–1837 (2022).
pubmed: 36196979 pmcid: 9639622 doi: 10.1002/acn3.51676
Bornhorst, J. A. et al. Plasma neurofilament light chain (NfL) reference interval determination in an age-stratified cognitively unimpaired cohort. Clin. Chim. Acta 535, 153–156 (2022).
pubmed: 36041549 doi: 10.1016/j.cca.2022.08.017
Borghi, E. et al. Construction of the World Health Organization child growth standards: selection of methods for attained growth curves. Stat. Med. 25, 247–265 (2006).
pubmed: 16143968 doi: 10.1002/sim.2227
Abdelhak, A. et al. Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study. Lancet Neurol. 22, 826–833 (2023).
pubmed: 37524100 doi: 10.1016/S1474-4422(23)00210-7
Wilson, D. et al. Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury. Clin. Chem. Lab. Med. 62, 322–331 (2023).
pubmed: 37702323 doi: 10.1515/cclm-2023-0518
Janiaud, P. et al. Personalized treatment decision algorithms for the clinical implementation of serum neurofilament light chain in multiple sclerosis: a modified Delphi study. Mult. Scler. J. 29, 650–1044 (2023).
Lycke, J. N., Karlsson, J. E., Andersen, O. & Rosengren, L. E. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 64, 402–404 (1998).
pubmed: 9527161 pmcid: 2170011 doi: 10.1136/jnnp.64.3.402
Rosengren, L. E., Karlsson, J. E., Karlsson, J. O., Persson, L. I. & Wikkelsø, C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J. Neurochem. 67, 2013–2018 (1996).
pubmed: 8863508 doi: 10.1046/j.1471-4159.1996.67052013.x
Delcoigne, B. et al. Blood neurofilament light levels segregate treatment effects in multiple sclerosis. Neurology 94, e1201–e1212 (2020).
pubmed: 32047070 pmcid: 7387108 doi: 10.1212/WNL.0000000000009097
Kuhle, J. et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology 92, e1007–e1015 (2019).
pubmed: 30737333 pmcid: 6442011 doi: 10.1212/WNL.0000000000007032
Bittner, S. et al. Clinical implications of serum neurofilament in newly diagnosed MS patients: a longitudinal multicentre cohort study. EBioMedicine 56, 102807 (2020).
pubmed: 32460167 pmcid: 7251380 doi: 10.1016/j.ebiom.2020.102807
Piehl, F. et al. Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Mult. Scler. 24, 1046–1054 (2018).
pubmed: 28627962 doi: 10.1177/1352458517715132
Ziemssen, T. et al. Prognostic value of serum neurofilament light chain for disease activity and worsening in patients with relapsing multiple sclerosis: results from the phase 3 ASCLEPIOS I and II trials. Front. Immunol. 13, 852563 (2022).
pubmed: 35432382 pmcid: 9009385 doi: 10.3389/fimmu.2022.852563
Bar-Or, A. et al. Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials. EBioMedicine 93, 104662 (2023).
pubmed: 37354600 pmcid: 10320523 doi: 10.1016/j.ebiom.2023.104662
Kapoor, R. et al. Natalizumab reduces serum concentrations of neurofilament light chain in secondary progressive multiple sclerosis patients from the phase 3 ASCEND study (S12.008). Neurology 92, https://doi.org/10.1212/WNL.92.15_supplement.S12.008 (2019).
Kuhle, J. et al. Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology 88, 826–831 (2017).
pubmed: 28148632 pmcid: 5331872 doi: 10.1212/WNL.0000000000003653
Røsjø, E. et al. Natural variation of vitamin D and neurofilament light chain in relapsing-remitting multiple sclerosis. Front. Neurol. 11, 329 (2020).
pubmed: 32425877 pmcid: 7205013 doi: 10.3389/fneur.2020.00329
Smolders, J. et al. Vitamin D
pubmed: 31657006 doi: 10.1111/ane.13185
Bridel, C. et al. Serum neurofilament light association with progression in natalizumab-treated patients with relapsing-remitting multiple sclerosis. Neurology 97, e1898–e1905 (2021).
pubmed: 34504023 doi: 10.1212/WNL.0000000000012752
Barro, C. et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain 141, 2382–2391 (2018).
pubmed: 29860296 doi: 10.1093/brain/awy154
Chitnis, T. et al. Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis. Ann. Clin. Transl. Neurol. 5, 1478–1491 (2018).
pubmed: 30564615 pmcid: 6292183 doi: 10.1002/acn3.638
Cantó, E. et al. Association between serum neurofilament light chain levels and long-term disease course among patients with multiple sclerosis followed up for 12 years. JAMA Neurol. 76, 1359 (2019).
pubmed: 31403661 pmcid: 6692664 doi: 10.1001/jamaneurol.2019.2137
Thebault, S. et al. Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis. Sci. Rep. 10, 10381 (2020).
pubmed: 32587320 pmcid: 7316736 doi: 10.1038/s41598-020-67504-6
Thebault, S. et al. High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS. Neurol. Neuroimmunol. Neuroinflamm. 6, e598 (2019).
pubmed: 31516913 pmcid: 6715458 doi: 10.1212/NXI.0000000000000598
Buchmann, A. et al. High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis. Eur. J. Neurol. 30, 1389–1399 (2023).
pubmed: 36779855 doi: 10.1111/ene.15742
Lie, I. A. et al. Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study. J. Neurol. Neurosurg. Psychiatry 93, 849–857 (2022).
pubmed: 35649699 doi: 10.1136/jnnp-2021-328568
Maggi, P. et al. Chronic white matter inflammation and serum neurofilament levels in multiple sclerosis. Neurology 97, e543–e553 (2021).
pubmed: 34088875 pmcid: 8424501 doi: 10.1212/WNL.0000000000012326
Abdelhak, A. et al. Neurofilament light chain elevation and disability progression in multiple sclerosis. JAMA Neurol. 80, 1317–1325 (2023).
pubmed: 37930670 doi: 10.1001/jamaneurol.2023.3997
Meier, S. et al. Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis. JAMA Neurol. 80, 287–297 (2023).
pubmed: 36745446 pmcid: 10011932 doi: 10.1001/jamaneurol.2022.5250
Voigt, I., Inojosa, H., Wenk, J., Akgün, K. & Ziemssen, T. Building a monitoring matrix for the management of multiple sclerosis. Autoimmun. Rev. 22, 103358 (2023).
pubmed: 37178996 doi: 10.1016/j.autrev.2023.103358
Miyazawa, I. et al. High CSF neurofilament heavy chain levels in neuromyelitis optica. Neurology 68, 865–867 (2007).
pubmed: 17353477 doi: 10.1212/01.wnl.0000256820.26489.17
Mariotto, S. et al. Neurofilament light chain serum levels reflect disease severity in MOG-Ab associated disorders. J. Neurol. Neurosurg. Psychiatry 90, 1293–1296 (2019).
pubmed: 30952681 doi: 10.1136/jnnp-2018-320287
Mariotto, S. et al. Serum neurofilament light chain in NMOSD and related disorders: comparison according to aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies status. Mult. Scler. J. Exp. Transl. Clin. 3, 205521731774309 (2017).
Watanabe, M. et al. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology 93, e1299–e1311 (2019).
pubmed: 31471502 doi: 10.1212/WNL.0000000000008160
Chang, X. et al. Serum neurofilament light and GFAP are associated with disease severity in inflammatory disorders with aquaporin-4 or myelin oligodendrocyte glycoprotein antibodies. Front. Immunol. 12, 647618 (2021).
pubmed: 33796113 pmcid: 8008082 doi: 10.3389/fimmu.2021.647618
Kim, H. et al. Longitudinal follow-up of serum biomarkers in patients with neuromyelitis optica spectrum disorder. Mult. Scler. 28, 512–521 (2022).
pubmed: 34212756 doi: 10.1177/13524585211024978
Kim, H. et al. Serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease. Neurol. Neuroimmunol. Neuroinflamm. 7, e708 (2020).
pubmed: 32184342 pmcid: 7136043 doi: 10.1212/NXI.0000000000000708
Lista, S. et al. Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer’s disease. Neurochem. Int. 108, 355–360 (2017).
pubmed: 28527630 doi: 10.1016/j.neuint.2017.05.010
Mattsson, N., Cullen, N. C., Andreasson, U., Zetterberg, H. & Blennow, K. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 76, 791–799 (2019).
pubmed: 31009028 pmcid: 6583067 doi: 10.1001/jamaneurol.2019.0765
Ashton, N. J. et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat. Commun. 12, 3400 (2021).
pubmed: 34099648 pmcid: 8185001 doi: 10.1038/s41467-021-23620-z
Dhiman, K. et al. Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer’s disease. Alzheimers Dement. 12, e12005 (2020).
Verberk, I. M. W. et al. Combination of plasma amyloid beta
pubmed: 32988409 pmcid: 7523295 doi: 10.1186/s13195-020-00682-7
Moore, E. E. et al. Neurofilament relates to white matter microstructure in older adults. Neurobiol. Aging 70, 233–241 (2018).
pubmed: 30036759 pmcid: 6119102 doi: 10.1016/j.neurobiolaging.2018.06.023
Meeker, K. L. et al. Cerebrospinal fluid neurofilament light chain is a marker of aging and white matter damage. Neurobiol. Dis. 166, 105662 (2022).
pubmed: 35167933 pmcid: 9112943 doi: 10.1016/j.nbd.2022.105662
Gaetani, L. et al. Neurofilament light chain as a biomarker in neurological disorders. J. Neurol. Neurosurg. Psychiatry 90, 870–881 (2019).
pubmed: 30967444 doi: 10.1136/jnnp-2018-320106
Benussi, A. et al. Diagnostic and prognostic value of serum NfL and p-Tau 181 in frontotemporal lobar degeneration. J. Neurol. Neurosurg. Psychiatry 91, 960–967 (2020).
pubmed: 32611664 doi: 10.1136/jnnp-2020-323487
Steinacker, P. et al. Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. Sci. Rep. 6, 38737 (2016).
pubmed: 27929120 pmcid: 5144074 doi: 10.1038/srep38737
Abu-Rumeileh, S. et al. The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias. Alzheimers Res. Ther. 10, 3 (2018).
pubmed: 29368621 pmcid: 5784714 doi: 10.1186/s13195-017-0331-1
Preische, O. et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease. Nat. Med. 25, 277–283 (2019).
pubmed: 30664784 pmcid: 6367005 doi: 10.1038/s41591-018-0304-3
Lleó, A. et al. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer’s disease continuum in the BIOMARKAPD study. Alzheimers Dement. 15, 742–753 (2019).
pubmed: 30967340 doi: 10.1016/j.jalz.2019.01.015
Zetterberg, H. et al. Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol. 73, 60–67 (2016).
pubmed: 26524180 pmcid: 5624219 doi: 10.1001/jamaneurol.2015.3037
Fortea, J. et al. Plasma and CSF biomarkers for the diagnosis of Alzheimer’s disease in adults with Down syndrome: a cross-sectional study. Lancet Neurol. 17, 860–869 (2018).
pubmed: 30172624 doi: 10.1016/S1474-4422(18)30285-0
Aamodt, W. W. et al. Neurofilament light chain as a biomarker for cognitive decline in Parkinson disease. Mov. Disord. 36, 2945–2950 (2021).
pubmed: 34480363 pmcid: 8688198 doi: 10.1002/mds.28779
Bäckström, D. C. et al. Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease. JAMA Neurol. 72, 1175–1182 (2015).
pubmed: 26258692 doi: 10.1001/jamaneurol.2015.1449
Hansson, O. et al. Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology 88, 930–937 (2017).
pubmed: 28179466 pmcid: 5333515 doi: 10.1212/WNL.0000000000003680
Koga, S., Sekiya, H., Kondru, N., Ross, O. A. & Dickson, D. W. Neuropathology and molecular diagnosis of synucleinopathies. Mol. Neurodegener. 16, 83 (2021).
pubmed: 34922583 pmcid: 8684287 doi: 10.1186/s13024-021-00501-z
Thijssen, E. H. et al. Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia. Alzheimers Dement. 14, e12285 (2022).
Baiardi, S. et al. Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias. Alzheimers Res. Ther. 14, 153 (2022).
pubmed: 36221099 pmcid: 9555092 doi: 10.1186/s13195-022-01093-6
The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J. Neurol. Neurosurg. Psychiatry 57, 416–418 (1994).
doi: 10.1136/jnnp.57.4.416
Grossman, M. et al. Frontotemporal lobar degeneration. Nat. Rev. Dis. Prim. 9, 40 (2023).
pubmed: 37563165 doi: 10.1038/s41572-023-00447-0
Forgrave, L. M., Ma, M., Best, J. R. & DeMarco, M. L. The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer’s disease, frontotemporal dementia, and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Alzheimers Dement. 11, 730–743 (2019).
Davy, V., Dumurgier, J., Fayosse, A., Paquet, C. & Cognat, E. Neurofilaments as emerging biomarkers of neuroaxonal damage to differentiate behavioral frontotemporal dementia from primary psychiatric disorders: a systematic review. Diagnostics 11, 754 (2021).
pubmed: 33922390 pmcid: 8146697 doi: 10.3390/diagnostics11050754
Al Shweiki, M. R. et al. Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. J. Psychiatr. Res. 113, 137–140 (2019).
pubmed: 30953863 doi: 10.1016/j.jpsychires.2019.03.019
Ducharme, S. et al. Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. Brain 143, 1632–1650 (2020).
pubmed: 32129844 pmcid: 7849953 doi: 10.1093/brain/awaa018
Willemse, E. A. J., Scheltens, P., Teunissen, C. E. & Vijverberg, E. G. B. A neurologist’s perspective on serum neurofilament light in the memory clinic: a prospective implementation study. Alzheimers Res. Ther. 13, 101 (2021).
pubmed: 34006321 pmcid: 8132439 doi: 10.1186/s13195-021-00841-4
Gendron, T. F. et al. Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders. Cell Rep. Med. 3, 100607 (2022).
pubmed: 35492244 pmcid: 9044101 doi: 10.1016/j.xcrm.2022.100607
Staffaroni, A. M. et al. Temporal order of clinical and biomarker changes in familial frontotemporal dementia. Nat. Med. 28, 2194–2206 (2022).
pubmed: 36138153 pmcid: 9951811 doi: 10.1038/s41591-022-01942-9
Giannini, L. A. A. et al. Clinical value of longitudinal serum neurofilament light chain in prodromal genetic frontotemporal dementia. Neurology 101, e1069–e1082 (2023).
pubmed: 37491327 pmcid: 10491440 doi: 10.1212/WNL.0000000000207581
Brettschneider, J., Petzold, A., Süssmuth, S. D., Ludolph, A. C. & Tumani, H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 66, 852–856 (2006).
pubmed: 16567701 doi: 10.1212/01.wnl.0000203120.85850.54
Zetterberg, H., Jacobsson, J., Rosengren, L., Blennow, K. & Andersen, P. M. Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. Eur. J. Neurol. 14, 1329–1333 (2007).
pubmed: 17903209 doi: 10.1111/j.1468-1331.2007.01972.x
Lu, C.-H. et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology 84, 2247–2257 (2015).
pubmed: 25934855 pmcid: 4456658 doi: 10.1212/WNL.0000000000001642
Menke, R. A. L. et al. CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann. Clin. Transl. Neurol. 2, 748–755 (2015).
pubmed: 26273687 pmcid: 4531057 doi: 10.1002/acn3.212
Steinacker, P. et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J. Neurol. Neurosurg. Psychiatry 87, 12–20 (2016).
pubmed: 26296871
Steinacker, P. et al. Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: data from the German MND-net. Amyotroph. Lateral Scler. Frontotemporal Degener. 18, 112–119 (2017).
pubmed: 27819158 doi: 10.1080/21678421.2016.1241279
De Schaepdryver, M. et al. Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 89, 367–373 (2018).
pubmed: 29054919 doi: 10.1136/jnnp-2017-316605
Schreiber, S. et al. Significance of CSF NfL and tau in ALS. J. Neurol. 265, 2633–2645 (2018).
pubmed: 30187162 doi: 10.1007/s00415-018-9043-0
Abu-Rumeileh, S. et al. Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis. J. Neurol. 267, 1699–1708 (2020).
pubmed: 32100123 doi: 10.1007/s00415-020-09761-z
Halbgebauer, S. et al. Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS. J. Neurol. Neurosurg. Psychiatry 93, 68–74 (2022).
pubmed: 34417339 doi: 10.1136/jnnp-2021-327129
Verde, F. et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 90, 157–164 (2019).
pubmed: 30309882 doi: 10.1136/jnnp-2018-318704
Meyer, T. et al. Performance of serum neurofilament light chain in a wide spectrum of clinical courses of amyotrophic lateral sclerosis-a cross-sectional multicenter study. Eur. J. Neurol. 30, 1600–1610 (2023).
pubmed: 36899448 doi: 10.1111/ene.15773
Abu-Rumeileh, S. et al. Comparison between plasma and cerebrospinal fluid biomarkers for the early diagnosis and association with survival in prion disease. J. Neurol. Neurosurg. Psychiatry 91, 1181–1188 (2020).
pubmed: 32928934 doi: 10.1136/jnnp-2020-323826
Halbgebauer, S. et al. Blood β-synuclein and neurofilament light chain during the course of prion disease. Neurology 98, e1434–e1445 (2022).
pubmed: 35110380 doi: 10.1212/WNL.0000000000200002
Gille, B. et al. Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with amyotrophic lateral sclerosis. Neuropathol. Appl. Neurobiol. 45, 291–304 (2019).
pubmed: 29908069 doi: 10.1111/nan.12511
Poesen, K. et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology 88, 2302–2309 (2017).
pubmed: 28500227 doi: 10.1212/WNL.0000000000004029
Oeckl, P. et al. Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosis. Acta Neuropathol. 139, 119–134 (2020).
pubmed: 31701227 doi: 10.1007/s00401-019-02093-x
Benatar, M., Wuu, J., Andersen, P. M., Lombardi, V. & Malaspina, A. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann. Neurol. 84, 130–139 (2018).
pubmed: 30014505 doi: 10.1002/ana.25276
Benatar, M. et al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology 95, e59–e69 (2020).
pubmed: 32385188 pmcid: 7371380 doi: 10.1212/WNL.0000000000009559
Thompson, A. G. et al. Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain. Brain Commun. 4, fcac029 (2022).
pubmed: 35224491 pmcid: 8870425 doi: 10.1093/braincomms/fcac029
Feneberg, E. et al. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology 90, e22–e30 (2018).
pubmed: 29212830 doi: 10.1212/WNL.0000000000004761
De Schaepdryver, M. et al. Serum neurofilament heavy chains as early marker of motor neuron degeneration. Ann. Clin. Transl. Neurol. 6, 1971–1979 (2019).
pubmed: 31518073 pmcid: 6801162 doi: 10.1002/acn3.50890
Bjornevik, K. et al. Prediagnostic neurofilament light chain levels in amyotrophic lateral sclerosis. Neurology 97, e1466–e1474 (2021).
pubmed: 34380747 pmcid: 8575132 doi: 10.1212/WNL.0000000000012632
Benatar, M. et al. Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph. Lateral Scler. Frontotemporal Degener. 20, 538–548 (2019).
pubmed: 31432691 pmcid: 6768722 doi: 10.1080/21678421.2019.1646769
Weydt, P. et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann. Neurol. 79, 152–158 (2016).
pubmed: 26528863 doi: 10.1002/ana.24552
Goutman, S. A. et al. Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurol. 21, 480–493 (2022).
pubmed: 35334233 pmcid: 9513753 doi: 10.1016/S1474-4422(21)00465-8
Boylan, K. B. et al. Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 84, 467–472 (2013).
pubmed: 23117489 doi: 10.1136/jnnp-2012-303768
Gendron, T. F. et al. Phosphorylated neurofilament heavy chain: a biomarker of survival for C9ORF72-associated amyotrophic lateral sclerosis. Ann. Neurol. 82, 139–146 (2017).
pubmed: 28628244 pmcid: 5676468 doi: 10.1002/ana.24980
Su, W.-M. et al. Predictors of survival in patients with amyotrophic lateral sclerosis: a large meta-analysis. EBioMedicine 74, 103732 (2021).
pubmed: 34864363 pmcid: 8646173 doi: 10.1016/j.ebiom.2021.103732
Devos, D. et al. A ferroptosis-based panel of prognostic biomarkers for amyotrophic lateral sclerosis. Sci. Rep. 9, 2918 (2019).
pubmed: 30814647 pmcid: 6393674 doi: 10.1038/s41598-019-39739-5
Shefner, J. M. et al. Amyotrophic lateral sclerosis clinical trials and interpretation of functional end points and fluid biomarkers: a review. JAMA Neurol. 79, 1312–1318 (2022).
pubmed: 36251310 doi: 10.1001/jamaneurol.2022.3282
Witzel, S. et al. Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials. Transl. Neurodegener. 10, 31 (2021).
pubmed: 34433481 pmcid: 8390195 doi: 10.1186/s40035-021-00257-y
Miller, T. et al. Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N. Engl. J. Med. 383, 109–119 (2020).
pubmed: 32640130 doi: 10.1056/NEJMoa2003715
Meyer, T. et al. Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: treatment experience in clinical practice. Muscle Nerve 67, 515–521 (2023).
pubmed: 36928619 doi: 10.1002/mus.27818
Benatar, M. et al. Design of a randomized, placebo-controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: the ATLAS study. Neurotherapeutics 19, 1248–1258 (2022).
pubmed: 35585374 pmcid: 9587202 doi: 10.1007/s13311-022-01237-4
Esselin, F. et al. Repeated neurofilament light chain measurements did not capture riluzole therapeutic effect in amyotrophic lateral sclerosis patients. CNS Neurosci. Ther. 28, 1532–1538 (2022).
pubmed: 35751632 pmcid: 9437233 doi: 10.1111/cns.13894
Shefner, J. M. et al. A proposal for new diagnostic criteria for ALS. Clin. Neurophysiol. 131, 1975–1978 (2020).
pubmed: 32387049 doi: 10.1016/j.clinph.2020.04.005
The German Neurological Society (DGN). Guidelines motoneuron diseases. dgn.org, https://dgn.org/leitlinie/motoneuronerkrankungen [in German] (2021).
Gattringer, T. et al. Serum neurofilament light is sensitive to active cerebral small vessel disease. Neurology 89, 2108–2114 (2017).
pubmed: 29046363 pmcid: 5711505 doi: 10.1212/WNL.0000000000004645
Tiedt, S. et al. Serum neurofilament light: a biomarker of neuroaxonal injury after ischemic stroke. Neurology 91, e1338–e1347 (2018).
pubmed: 30217937 doi: 10.1212/WNL.0000000000006282
Pedersen, A. et al. Circulating neurofilament light in ischemic stroke: temporal profile and outcome prediction. J. Neurol. 266, 2796–2806 (2019).
pubmed: 31375988 pmcid: 6803587 doi: 10.1007/s00415-019-09477-9
Gendron, T. F. et al. Plasma neurofilament light predicts mortality in patients with stroke. Sci. Transl. Med. 12, eaay1913 (2020).
pubmed: 33177179 pmcid: 9534269 doi: 10.1126/scitranslmed.aay1913
Sanchez, J. D. et al. Temporal patterning of neurofilament light as a blood-based biomarker for stroke: a systematic review and meta-analysis. Front. Neurol. 13, 841898 (2022).
pubmed: 35651349 pmcid: 9149427 doi: 10.3389/fneur.2022.841898
De Marchis, G. M. et al. Serum neurofilament light chain in patients with acute cerebrovascular events. Eur. J. Neurol. 25, 562–568 (2018).
pubmed: 29281157 doi: 10.1111/ene.13554
Onatsu, J. et al. Serum neurofilament light chain concentration correlates with infarct volume but not prognosis in acute ischemic stroke. J. Stroke Cerebrovasc. Dis. 28, 2242–2249 (2019).
pubmed: 31151840 doi: 10.1016/j.jstrokecerebrovasdis.2019.05.008
Traenka, C. et al. Serum neurofilament light chain levels are associated with clinical characteristics and outcome in patients with cervical artery dissection. Cerebrovasc. Dis. 40, 222–227 (2015).
pubmed: 26418549 doi: 10.1159/000440774
Pujol-Calderón, F. et al. Neurofilament changes in serum and cerebrospinal fluid after acute ischemic stroke. Neurosci. Lett. 698, 58–63 (2019).
pubmed: 30599262 doi: 10.1016/j.neulet.2018.12.042
Uphaus, T. et al. NfL (neurofilament light chain) levels as a predictive marker for long-term outcome after ischemic stroke. Stroke 50, 3077–3084 (2019).
pubmed: 31537188 doi: 10.1161/STROKEAHA.119.026410
Wang, P., Fan, J., Yuan, L., Nan, Y. & Nan, S. Serum neurofilament light predicts severity and prognosis in patients with ischemic stroke. Neurotox. Res. 37, 987–995 (2020).
pubmed: 31898161 doi: 10.1007/s12640-019-00159-y
Rahmig, J. et al. Serum neurofilament light chain levels are associated with stroke severity and functional outcome in patients undergoing endovascular therapy for large vessel occlusion. J. Neurol. Sci. 429, 118063 (2021).
pubmed: 34488043 doi: 10.1016/j.jns.2021.118063
Jacob, M. A. et al. Increased neurofilament light chain is associated with increased risk of long-term mortality in cerebral small vessel disease. J. Stroke 24, 296–299 (2022).
pubmed: 35677985 pmcid: 9194543 doi: 10.5853/jos.2021.04385
Duering, M. et al. Serum neurofilament light chain levels are related to small vessel disease burden. J. Stroke 20, 228–238 (2018).
pubmed: 29886723 pmcid: 6007291 doi: 10.5853/jos.2017.02565
Peters, N. et al. Serum neurofilament light chain is associated with incident lacunes in progressive cerebral small vessel disease. J. Stroke 22, 369–376 (2020).
pubmed: 33053952 pmcid: 7568975 doi: 10.5853/jos.2019.02845
Peters, N. Neurofilament light chain as a biomarker in cerebral small-vessel disease. Mol. Diagn. Ther. 26, 1–6 (2022).
pubmed: 34825310 doi: 10.1007/s40291-021-00566-y
Gravesteijn, G. et al. Serum neurofilament light correlates with CADASIL disease severity and survival. Ann. Clin. Transl. Neurol. 6, 46–56 (2019).
pubmed: 30656183 doi: 10.1002/acn3.678
Chen, C.-H., Cheng, Y.-W., Chen, Y.-F., Tang, S.-C. & Jeng, J.-S. Plasma neurofilament light chain and glial fibrillary acidic protein predict stroke in CADASIL. J. Neuroinflammation 17, 124 (2020).
pubmed: 32321529 pmcid: 7175500 doi: 10.1186/s12974-020-01813-5
Zhang, X., Wang, H., Li, L., Deng, X. & Bo, L. Neurofilament light chain: a candidate biomarker of perioperative stroke. Front. Aging Neurosci. 14, 921809 (2022).
pubmed: 35875791 pmcid: 9300966 doi: 10.3389/fnagi.2022.921809
Taylor, J. et al. Perioperative ischaemic brain injury and plasma neurofilament light: a secondary analysis of two prospective cohort studies. Br. J. Anaesth. 130, e361–e369 (2023).
pubmed: 36437124 doi: 10.1016/j.bja.2022.10.018
Pinter, D. et al. Longitudinal MRI dynamics of recent small subcortical infarcts and possible predictors. J. Cereb. Blood Flow. Metab. 39, 1669–1677 (2019).
pubmed: 29737904 doi: 10.1177/0271678X18775215
Egle, M. et al. Neurofilament light chain predicts future dementia risk in cerebral small vessel disease. J. Neurol. Neurosurg. Psychiatry 92, 582–589 (2021).
pubmed: 33558370 doi: 10.1136/jnnp-2020-325681
Heshmatollah, A. et al. Plasma β-amyloid, total-tau, and neurofilament light chain levels and the risk of stroke: a prospective population-based study. Neurology 98, e1729–e1737 (2022).
pubmed: 35232820 doi: 10.1212/WNL.0000000000200004
Korley, F. K. et al. Serum NfL (neurofilament light chain) levels and incident stroke in adults with diabetes mellitus. Stroke 50, 1669–1675 (2019).
pubmed: 31138085 pmcid: 6591022 doi: 10.1161/STROKEAHA.119.024941
Polymeris, A. A. et al. Renal function and body mass index contribute to serum neurofilament light chain levels in elderly patients with atrial fibrillation. Front. Neurosci. 16, 819010 (2022).
pubmed: 35495025 pmcid: 9047720 doi: 10.3389/fnins.2022.819010
Lota, K. S. et al. Rotational head acceleration and traumatic brain injury in combat sports: a systematic review. Br. Med. Bull. 141, 33–46 (2022).
pubmed: 35107134 pmcid: 9351374 doi: 10.1093/bmb/ldac002
Bergman, J. et al. Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS. Neurol. Neuroimmunol. Neuroinflamm. 3, e271 (2016).
pubmed: 27536708 pmcid: 4972001 doi: 10.1212/NXI.0000000000000271
Shahim, P. et al. Serum neurofilament light protein predicts clinical outcome in traumatic brain injury. Sci. Rep. 6, 36791 (2016).
pubmed: 27819296 pmcid: 5098187 doi: 10.1038/srep36791
Gill, J. et al. Glial fibrillary acidic protein elevations relate to neuroimaging abnormalities after mild TBI. Neurology 91, e1385–e1389 (2018).
pubmed: 30209234 pmcid: 6177279 doi: 10.1212/WNL.0000000000006321
Iverson, G. L. et al. Serum neurofilament light is elevated differentially in older adults with uncomplicated mild traumatic brain injuries. J. Neurotrauma 36, 2400–2406 (2019).
pubmed: 30843469 doi: 10.1089/neu.2018.6341
Hossain, I. et al. Early levels of glial fibrillary acidic protein and neurofilament light protein in predicting the outcome of mild traumatic brain injury. J. Neurotrauma 36, 1551–1560 (2019).
pubmed: 30489229 doi: 10.1089/neu.2018.5952
Shahim, P. et al. Neurofilament light as a biomarker in traumatic brain injury. Neurology 95, e610–e622 (2020).
pubmed: 32641538 pmcid: 7455357 doi: 10.1212/WNL.0000000000009983
Shahim, P., Tegner, Y., Marklund, N., Blennow, K. & Zetterberg, H. Neurofilament light and tau as blood biomarkers for sports-related concussion. Neurology 90, e1780–e1788 (2018).
pubmed: 29653990 pmcid: 5957307 doi: 10.1212/WNL.0000000000005518
Shahim, P., Zetterberg, H., Tegner, Y. & Blennow, K. Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports. Neurology 88, 1788–1794 (2017).
pubmed: 28404801 pmcid: 5419986 doi: 10.1212/WNL.0000000000003912
Farragher, C. D., Ku, Y. & Powers, J. E. The potential role of neurofilament light in mild traumatic brain injury diagnosis: a systematic review. Cureus 14, e31301 (2022).
pubmed: 36514599 pmcid: 9733779
Thelin, E. et al. A serum protein biomarker panel improves outcome prediction in human traumatic brain injury. J. Neurotrauma 36, 2850–2862 (2019).
pubmed: 31072225 pmcid: 6761606 doi: 10.1089/neu.2019.6375
Barro, C., Chitnis, T. & Weiner, H. L. Blood neurofilament light: a critical review of its application to neurologic disease. Ann. Clin. Transl. Neurol. 7, 2508–2523 (2020).
pubmed: 33146954 pmcid: 7732243 doi: 10.1002/acn3.51234
Rosén, H., Karlsson, J.-E. & Rosengren, L. CSF levels of neurofilament is a valuable predictor of long-term outcome after cardiac arrest. J. Neurological Sci. 221, 19–24 (2004).
doi: 10.1016/j.jns.2004.03.003
Rana, O. R. et al. Neurofilament light chain as an early and sensitive predictor of long-term neurological outcome in patients after cardiac arrest. Int. J. Cardiol. 168, 1322–1327 (2013).
pubmed: 23287695 doi: 10.1016/j.ijcard.2012.12.016
Rosén, C. et al. Cerebrospinal fluid biomarkers in cardiac arrest survivors. Resuscitation 85, 227–232 (2014).
pubmed: 24231570 doi: 10.1016/j.resuscitation.2013.10.032
Rundgren, M., Friberg, H., Cronberg, T., Romner, B. & Petzold, A. Serial soluble neurofilament heavy chain in plasma as a marker of brain injury after cardiac arrest. Crit. Care 16, R45 (2012).
pubmed: 22410303 pmcid: 3681370 doi: 10.1186/cc11244
Abu-Rumeileh, S. et al. The multifaceted role of neurofilament light chain protein in non-primary neurological diseases. Brain 146, 421–427 (2022).
doi: 10.1093/brain/awac328
Moseby-Knappe, M. et al. Serum neurofilament light chain for prognosis of outcome after cardiac arrest. JAMA Neurol. 76, 64 (2019).
pubmed: 30383090 doi: 10.1001/jamaneurol.2018.3223
Disanto, G. et al. Serum neurofilament light chain as a prognostic marker in postanoxic encephalopathy. Epilepsy Behav. 101, 106432 (2019).
pubmed: 31375414 doi: 10.1016/j.yebeh.2019.07.033
Fisse, A. L. et al. Serum neurofilament light chain as outcome marker for intensive care unit patients. J. Neurol. 268, 1323–1329 (2021).
pubmed: 33098034 doi: 10.1007/s00415-020-10277-9
Wihersaari, L. et al. Neurofilament light as an outcome predictor after cardiac arrest: a post hoc analysis of the COMACARE trial. Intensive Care Med. 47, 39–48 (2021).
pubmed: 32852582 doi: 10.1007/s00134-020-06218-9
Wihersaari, L. et al. Neurofilament light compared to neuron-specific enolase as a predictor of unfavourable outcome after out-of-hospital cardiac arrest. Resuscitation 174, 1–8 (2022).
pubmed: 35245610 doi: 10.1016/j.resuscitation.2022.02.024
Hunziker, S. et al. Serum neurofilament measurement improves clinical risk scores for outcome prediction after cardiac arrest: results of a prospective study. Crit. Care 25, 32 (2021).
pubmed: 33472689 pmcid: 7819224 doi: 10.1186/s13054-021-03459-y
Andersson, P. et al. Predicting neurological outcome after out-of-hospital cardiac arrest with cumulative information; development and internal validation of an artificial neural network algorithm. Crit. Care 25, 83 (2021).
pubmed: 33632280 pmcid: 7905905 doi: 10.1186/s13054-021-03505-9
Blennow Nordström, E. et al. Serum neurofilament light levels are correlated to long-term neurocognitive outcome measures after cardiac arrest. Brain Inj. 36, 800–809 (2022).
pubmed: 35253570 doi: 10.1080/02699052.2022.2048693
Pouplet, C. et al. The accuracy of various neuro-prognostication algorithms and the added value of neurofilament light chain dosage for patients resuscitated from shockable cardiac arrest: an ancillary analysis of the ISOCRATE study. Resuscitation 171, 1–7 (2022).
pubmed: 34915084 doi: 10.1016/j.resuscitation.2021.12.009
Levin, H. et al. Plasma neurofilament light is a predictor of neurological outcome 12 h after cardiac arrest. Crit. Care 27, 74 (2023).
pubmed: 36829239 pmcid: 9960417 doi: 10.1186/s13054-023-04355-3
Adler, C. et al. Absolute serum neurofilament light chain levels and its early kinetics predict brain injury after out-of-hospital cardiac arrest. J. Neurol. 269, 1530–1537 (2022).
pubmed: 34328545 doi: 10.1007/s00415-021-10722-3
Kirschen, M. P. et al. Circulating neurofilament light chain is associated with survival after pediatric cardiac arrest*. Pediatr. Crit. Care Med. 21, 656–661 (2020).
pubmed: 32224828 pmcid: 9148182 doi: 10.1097/PCC.0000000000002294
Fink, E. L. et al. Association of blood-based brain injury biomarker concentrations with outcomes after pediatric cardiac arrest. JAMA Netw. Open 5, e2230518 (2022).
pubmed: 36074465 pmcid: 9459665 doi: 10.1001/jamanetworkopen.2022.30518
Hoiland, R. L. et al. Neurologic prognostication after cardiac arrest using brain biomarkers: a systematic review and meta-analysis. JAMA Neurol. 79, 390–398 (2022).
pubmed: 35226054 pmcid: 8886448 doi: 10.1001/jamaneurol.2021.5598
Fu, Y. et al. Neuroprognostication value of serum neurofilament light chain for out-of-hospital cardiac arrest: a systematic review and meta-analysis. PLoS ONE 18, e0290619 (2023).
pubmed: 37713399 pmcid: 10503738 doi: 10.1371/journal.pone.0290619
Ashton, N. J. et al. Alzheimer disease blood biomarkers in patients with out-of-hospital cardiac arrest. JAMA Neurol. 80, 388–396 (2023).
pubmed: 36877496 pmcid: 9989959 doi: 10.1001/jamaneurol.2023.0050
Wang, S. L., Li, N., Feng, S. Y. & Li, Y. Serum neurofilament light chain as a predictive marker of neurologic outcome after cardiac arrest: a meta-analysis. BMC Cardiovasc. Disord. 23, 193 (2023).
pubmed: 37061702 pmcid: 10105388 doi: 10.1186/s12872-023-03220-z
Nolan, J. P. et al. European Resuscitation Council and European Society of Intensive Care Medicine guidelines 2021: post-resuscitation care. Intensive Care Med 47, 369–421 (2021).
pubmed: 33765189 pmcid: 7993077 doi: 10.1007/s00134-021-06368-4
Panchal, A. R. et al. Part 3: adult basic and advanced life support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 142, S366–S468 (2020).
pubmed: 33081529 doi: 10.1161/CIR.0000000000000916
Moseby-Knappe, M. et al. Serum markers of brain injury can predict good neurological outcome after out-of-hospital cardiac arrest. Intensive Care Med. 47, 984–994 (2021).
pubmed: 34417831 pmcid: 8421280 doi: 10.1007/s00134-021-06481-4
Lybeck, A. et al. Postanoxic electrographic status epilepticus and serum biomarkers of brain injury. Resuscitation 158, 253–257 (2021).
pubmed: 33127439 doi: 10.1016/j.resuscitation.2020.10.027
Grindegård, L. et al. Association between EEG patterns and serum neurofilament light after cardiac arrest: a post hoc analysis of the TTM trial. Neurology 98, e2487–e2498 (2022).
pubmed: 35470143 pmcid: 9231840 doi: 10.1212/WNL.0000000000200335
Lagebrant, A. et al. Brain injury markers in blood predict signs of hypoxic ischaemic encephalopathy on head computed tomography after cardiac arrest. Resuscitation 184, 109668 (2023).
pubmed: 36563954 doi: 10.1016/j.resuscitation.2022.12.006
Tolosa, E., Garrido, A., Scholz, S. W. & Poewe, W. Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol. 20, 385–397 (2021).
pubmed: 33894193 pmcid: 8185633 doi: 10.1016/S1474-4422(21)00030-2
Siderowf, A. et al. Assessment of heterogeneity among participants in the Parkinson’s progression markers initiative cohort using α-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 22, 407–417 (2023).
pubmed: 37059509 pmcid: 10627170 doi: 10.1016/S1474-4422(23)00109-6
Quadalti, C. et al. Neurofilament light chain and α-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes. NPJ Parkinsons Dis. 7, 93 (2021).
pubmed: 34635674 pmcid: 8505434 doi: 10.1038/s41531-021-00232-4
Holmberg, B., Rosengren, L., Karlsson, J. E. & Johnels, B. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson’s disease. Mov. Disord. 13, 70–77 (1998).
pubmed: 9452329 doi: 10.1002/mds.870130116
Brettschneider, J. et al. Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes. Mov. Disord. 21, 2224–2227 (2006).
pubmed: 17013909 doi: 10.1002/mds.21124
Hall, S. et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch. Neurol. 69, 1445–1452 (2012).
pubmed: 22925882 doi: 10.1001/archneurol.2012.1654
Magdalinou, N. K. et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J. Neurol. Neurosurg. Psychiatry 86, 1240–1247 (2015).
pubmed: 25589779 doi: 10.1136/jnnp-2014-309562
Mollenhauer, B. et al. Validation of serum neurofilament light chain as a biomarker of Parkinson’s disease progression. Mov. Disord. 35, 1999–2008 (2020).
pubmed: 32798333 pmcid: 8017468 doi: 10.1002/mds.28206
Marques, T. M. et al. Serum NFL discriminates Parkinson disease from atypical parkinsonisms. Neurology 92, e1479–e1486 (2019).
pubmed: 30814322 doi: 10.1212/WNL.0000000000007179
Peng, L. et al. Diagnostic and prognostic performance of plasma neurofilament light chain in multiple system atrophy: a cross-sectional and longitudinal study. J. Neurol. 270, 4248–4261 (2023).
pubmed: 37184660 doi: 10.1007/s00415-023-11741-y
Angelopoulou, E. et al. CSF and circulating NfL as biomarkers for the discrimination of Parkinson disease from atypical parkinsonian syndromes: meta-analysis. Neurol. Clin. Pract. 11, e867–e875 (2021).
pubmed: 34992970 pmcid: 8723936 doi: 10.1212/CPJ.0000000000001116
Martinez-Valbuena, I. et al. Combining skin α-synuclein real-time quaking-induced conversion and circulating neurofilament light chain to distinguish multiple system atrophy and Parkinson’s disease. Mov. Disord. 37, 648–650 (2022).
pubmed: 35019153 doi: 10.1002/mds.28912
Bäckström, D. et al. NfL as a biomarker for neurodegeneration and survival in Parkinson disease. Neurology 95, e827–e838 (2020).
pubmed: 32680941 pmcid: 7605503 doi: 10.1212/WNL.0000000000010084
Rojas, J. C. et al. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology 90, e273–e281 (2018).
pubmed: 29282336 pmcid: 5798651 doi: 10.1212/WNL.0000000000004859
Batzu, L. et al. Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease. NPJ Parkinsons Dis. 8, 154 (2022).
pubmed: 36371469 pmcid: 9653432 doi: 10.1038/s41531-022-00384-x
Chelban, V. et al. Neurofilament light levels predict clinical progression and death in multiple system atrophy. Brain 145, 4398–4408 (2022).
pubmed: 35903017 pmcid: 9762941 doi: 10.1093/brain/awac253
Vijiaratnam, N. et al. Combining biomarkers for prognostic modelling of Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 93, 707–715 (2022).
pubmed: 35577512 doi: 10.1136/jnnp-2021-328365
Ygland Rödström, E., Mattsson-Carlgren, N., Janelidze, S., Hansson, O. & Puschmann, A. Serum neurofilament light chain as a marker of progression in Parkinson’s disease: long-term observation and implications of clinical subtypes. J. Parkinsons Dis. 12, 571–584 (2022).
pubmed: 34806619 pmcid: 8925110 doi: 10.3233/JPD-212866
Donker Kaat, L. et al. Serum neurofilament light chain in progressive supranuclear palsy. Parkinsonism Relat. Disord. 56, 98–101 (2018).
pubmed: 29937097 doi: 10.1016/j.parkreldis.2018.06.018
Oosterveld, L. P. et al. CSF biomarkers reflecting protein pathology and axonal degeneration are associated with memory, attentional, and executive functioning in early-stage Parkinson’s disease. Int. J. Mol. Sci. 21, 8519 (2020).
pubmed: 33198266 pmcid: 7697681 doi: 10.3390/ijms21228519
Barba, L. et al. CSF synaptic biomarkers in AT(N)-based subgroups of Lewy body disease. Neurology 101, e50–e62 (2023).
pubmed: 37188538 doi: 10.1212/WNL.0000000000207371
Ye, R. et al. Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson’s disease: an 8-year longitudinal study. Parkinsonism Relat. Disord. 85, 11–16 (2021).
pubmed: 33639572 pmcid: 8714021 doi: 10.1016/j.parkreldis.2021.02.008
Yang, D. et al. Neurofilament light chain as a mediator between LRRK2 mutation and dementia in Parkinson’s disease. NPJ Parkinsons Dis. 9, 132 (2023).
pubmed: 37699957 pmcid: 10497522 doi: 10.1038/s41531-023-00572-3
Singer, W. et al. Alpha-synuclein oligomers and neurofilament light chain predict phenoconversion of pure autonomic failure. Ann. Neurol. 89, 1212–1220 (2021).
pubmed: 33881777 pmcid: 8168720 doi: 10.1002/ana.26089
Park, D. G. et al. Neurofilament light chain and cardiac MIBG uptake as predictors for phenoconversion in isolated REM sleep behavior disorder. J. Neurol. 270, 4393–4402 (2023).
pubmed: 37233802 doi: 10.1007/s00415-023-11785-0
Zhang, X. et al. Neurofilament light protein predicts disease progression in idiopathic REM sleep behavior disorder. J. Parkinsons Dis. 13, 485–499 (2023).
pubmed: 37182898 pmcid: 10357151 doi: 10.3233/JPD-223519
Byrne, L. M. et al. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington’s disease: a retrospective cohort analysis. Lancet Neurol. 16, 601–609 (2017).
pubmed: 28601473 pmcid: 5507767 doi: 10.1016/S1474-4422(17)30124-2
Byrne, L. M. et al. Neurofilament light protein as a potential blood biomarker for Huntington’s disease in children. Mov. Disord. 37, 1526–1531 (2022).
pubmed: 35437792 pmcid: 9308659 doi: 10.1002/mds.29027
Gregory, S. et al. Characterizing white matter in Huntington’s disease. Mov. Disord. Clin. Pract. 7, 52–60 (2020).
pubmed: 31970212 doi: 10.1002/mdc3.12866
Scahill, R. I. et al. Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington’s disease Young Adult Study (HD-YAS): a cross-sectional analysis. Lancet Neurol. 19, 502–512 (2020).
pubmed: 32470422 pmcid: 7254065 doi: 10.1016/S1474-4422(20)30143-5
Parkin, G. M., Corey-Bloom, J., Snell, C., Castleton, J. & Thomas, E. A. Plasma neurofilament light in Huntington’s disease: a marker for disease onset, but not symptom progression. Parkinsonism Relat. Disord. 87, 32–38 (2021).
pubmed: 33940564 pmcid: 9083556 doi: 10.1016/j.parkreldis.2021.04.017
Parkin, G. M. et al. Associations between prognostic index scores and plasma neurofilament light in Huntington’s disease. Parkinsonism Relat. Disord. 97, 25–28 (2022).
pubmed: 35276585 pmcid: 9127124 doi: 10.1016/j.parkreldis.2022.02.023
Byrne, L. M. et al. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington’s disease. Sci. Transl. Med. 10, eaat7108 (2018).
pubmed: 30209243 doi: 10.1126/scitranslmed.aat7108
Rodrigues, F. B. et al. Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington’s disease. Sci. Transl. Med. 12, eabc2888 (2020).
pubmed: 33328328 pmcid: 7611886 doi: 10.1126/scitranslmed.abc2888
Feasby, T. E. et al. An acute axonal form of Guillain-Barré polyneuropathy. Brain 109, 1115–1126 (1986).
pubmed: 3790970 doi: 10.1093/brain/109.6.1115
Petzold, A. et al. CSF neurofilament levels: a potential prognostic marker in Guillain-Barré syndrome. Neurology 67, 1071–1073 (2006).
pubmed: 17000982 doi: 10.1212/01.wnl.0000237334.69665.92
Axelsson, M. et al. Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-Barré syndrome: a pilot study. Acta Neurol. Scand. 138, 143–150 (2018).
pubmed: 29624650 doi: 10.1111/ane.12927
Petzold, A. et al. CSF protein biomarkers for proximal axonal damage improve prognostic accuracy in the acute phase of Guillain-Barré syndrome. Muscle Nerve 40, 42–49 (2009).
pubmed: 19533642 doi: 10.1002/mus.21239
Altmann, P. et al. Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndrome. J. Neuroinflammation 17, 86 (2020).
pubmed: 32183837 pmcid: 7079539 doi: 10.1186/s12974-020-01737-0
Körtvelyessy, P. et al. Ratio and index of Neurofilament light chain indicate its origin in Guillain-Barré syndrome. Ann. Clin. Transl. Neurol. 7, 2213–2220 (2020).
pubmed: 33030817 pmcid: 7664266 doi: 10.1002/acn3.51207
Martín-Aguilar, L. et al. Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patients. J. Neurol. Neurosurg. Psychiatry https://doi.org/10.1136/jnnp-2020-323899 (2020).
doi: 10.1136/jnnp-2020-323899 pubmed: 33154183
Dujmovic, I., Lunn, M. P., Reilly, M. M. & Petzold, A. Serial cerebrospinal fluid neurofilament heavy chain levels in severe Guillain-Barré syndrome. Muscle Nerve 48, 132–134 (2013).
pubmed: 23716297 doi: 10.1002/mus.23752
Jin, M. et al. Cerebrospinal fluid neurofilament light chain predicts short-term prognosis in pediatric Guillain-Barré syndrome. Front. Neurol. 13, 972367 (2022).
pubmed: 36071910 pmcid: 9441703 doi: 10.3389/fneur.2022.972367
Sandelius, Å. et al. Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology 90, e518–e524 (2018).
pubmed: 29321234 pmcid: 5818017 doi: 10.1212/WNL.0000000000004932
Bomont, P. et al. The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy. Nat. Genet. 26, 370–374 (2000).
pubmed: 11062483 doi: 10.1038/81701
Mariotto, S. et al. Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies. J. Peripher. Nerv. Syst. 23, 174–177 (2018).
pubmed: 29974556 doi: 10.1111/jns.12279
van Lieverloo, G. G. A. et al. Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. J. Peripher. Nerv. Syst. 24, 187–194 (2019).
pubmed: 30973667 doi: 10.1111/jns.12319
Karam, C. Chronic inflammatory demyelinating polyradiculoneuropathy: five new things. Neurol. Clin. Pract. 12, 258–262 (2022).
pubmed: 35747539 pmcid: 9208411 doi: 10.1212/CPJ.0000000000001150
Kapoor, M. et al. Association of plasma neurofilament light chain with disease activity in chronic inflammatory demyelinating polyradiculoneuropathy. Eur. J. Neurol. 29, 3347–3357 (2022).
pubmed: 35837802 pmcid: 9796374 doi: 10.1111/ene.15496
Kmezic, I. et al. Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies. Eur. J. Neurol. 29, 2810–2822 (2022).
pubmed: 35638376 pmcid: 9542418 doi: 10.1111/ene.15428
Kim, S.-H. et al. Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy. Sci. Rep. 10, 7995 (2020).
pubmed: 32409710 pmcid: 7224372 doi: 10.1038/s41598-020-64511-5
Huehnchen, P. et al. Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy. JCI Insight 7, e154395 (2022).
pubmed: 35133982 pmcid: 8986065 doi: 10.1172/jci.insight.154395
Bischof, A. et al. Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy. Ann. Rheum. Dis. 77, 1093–1094 (2018).
pubmed: 28743789 doi: 10.1136/annrheumdis-2017-212045
Rossor, A. M. et al. A longitudinal and cross-sectional study of plasma neurofilament light chain concentration in Charcot-Marie-Tooth disease. J. Peripher. Nerv. Syst. 27, 50–57 (2022).
pubmed: 34851050 doi: 10.1111/jns.12477
Millere, E. et al. Plasma neurofilament light chain as a potential biomarker in Charcot-Marie-Tooth disease. Eur. J. Neurol. 28, 974–981 (2021).
pubmed: 33340200 doi: 10.1111/ene.14689
Rossor, A. M. et al. Plasma neurofilament heavy chain is not a useful biomarker in Charcot-Marie-Tooth disease. Muscle Nerve 53, 972–975 (2016).
pubmed: 27015106 doi: 10.1002/mus.25124
Kapoor, M. et al. Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis. J. Peripher. Nerv. Syst. 24, 314–319 (2019).
pubmed: 31583784 doi: 10.1111/jns.12350
Ticau, S. et al. Neurofilament light chain as a biomarker of hereditary transthyretin-mediated amyloidosis. Neurology 96, e412–e422 (2021).
pubmed: 33087494 pmcid: 7884985 doi: 10.1212/WNL.0000000000011090
Maia, L. F. et al. Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy. Amyloid 27, 97–102 (2020).
pubmed: 31906707 doi: 10.1080/13506129.2019.1708716
Carroll, A. S. et al. Serum neurofilament light chain in hereditary transthyretin amyloidosis: validation in real-life practice. Amyloid https://doi.org/10.1080/13506129.2024.2313218 (2024).
doi: 10.1080/13506129.2024.2313218 pubmed: 38348665
Faravelli, I. et al. Nusinersen treatment and cerebrospinal fluid neurofilaments: an explorative study on spinal muscular atrophy type 3 patients. J. Cell Mol. Med. 24, 3034–3039 (2020).
pubmed: 32032473 pmcid: 7077557 doi: 10.1111/jcmm.14939
Kong, L. et al. Impaired prenatal motor axon development necessitates early therapeutic intervention in severe SMA. Sci. Transl. Med. 13, eabb6871 (2021).
pubmed: 33504650 pmcid: 8208236 doi: 10.1126/scitranslmed.abb6871
Darras, B. T. et al. Neurofilament as a potential biomarker for spinal muscular atrophy. Ann. Clin. Transl. Neurol. 6, 932–944 (2019).
pubmed: 31139691 pmcid: 6530526 doi: 10.1002/acn3.779
Nitz, E. et al. Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children. Ann. Clin. Transl. Neurol. 8, 2013–2024 (2021).
pubmed: 34482646 pmcid: 8528467 doi: 10.1002/acn3.51449
Jin, J. et al. Plasma neurofilament light chain in Chinese children with later-onset spinal muscular atrophy. Clin. Chem. Lab. Med. 60, e237–e239 (2022).
pubmed: 35953879 doi: 10.1515/cclm-2022-0637
Reilly, A. et al. Central and peripheral delivered AAV9-SMN are both efficient but target different pathomechanisms in a mouse model of spinal muscular atrophy. Gene Ther. 29, 544–554 (2022).
pubmed: 35462564 doi: 10.1038/s41434-022-00338-1
Ru, Y. et al. Neurofilament light is a treatment-responsive biomarker in CLN2 disease. Ann. Clin. Transl. Neurol. 6, 2437–2447 (2019).
pubmed: 31814335 pmcid: 6917340 doi: 10.1002/acn3.50942
Wurster, C. D. et al. Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment. Ther. Adv. Neurol. Disord. 12, 1756286419846058 (2019).
pubmed: 31205491 pmcid: 6535708 doi: 10.1177/1756286419846058
Finkel, R. S. et al. Scientific rationale for a higher dose of nusinersen. Ann. Clin. Transl. Neurol. 9, 819–829 (2022).
pubmed: 35567345 pmcid: 9186144 doi: 10.1002/acn3.51562
De Wel, B., De Schaepdryver, M., Poesen, K. & Claeys, K. G. Biochemical and clinical biomarkers in adult SMA 3-4 patients treated with nusinersen for 22 months. Ann. Clin. Transl. Neurol. 9, 1241–1251 (2022).
pubmed: 35833245 pmcid: 9380134 doi: 10.1002/acn3.51625
Wilke, C. et al. Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice. EMBO Mol. Med. 12, e11803 (2020).
pubmed: 32510847 pmcid: 7338806 doi: 10.15252/emmm.201911803
Peng, Y. et al. Association of serum neurofilament light and disease severity in patients with spinocerebellar ataxia type 3. Neurology 95, e2977–e2987 (2020).
pubmed: 32817181 doi: 10.1212/WNL.0000000000010671
Peng, L. et al. Blood neurofilament light chain in genetic ataxia: a meta-analysis. Mov. Disord. 37, 171–181 (2022).
pubmed: 34519102 doi: 10.1002/mds.28783
Oender, D. et al. Evolution of clinical outcome measures and biomarkers in sporadic adult-onset degenerative ataxia. Mov. Disord. 38, 654–664 (2023).
pubmed: 36695111 doi: 10.1002/mds.29324
Agrawal, N. et al. Neurofilament light chain in cerebrospinal fluid as a novel biomarker in evaluating both clinical severity and therapeutic response in Niemann-Pick disease type C1. Genet. Med. 25, 100349 (2023).
pubmed: 36470574 doi: 10.1016/j.gim.2022.11.017
Nass, R. D. et al. Serum biomarkers of cerebral cellular stress after self-limiting tonic clonic seizures: an exploratory study. Seizure 85, 1–5 (2021).
pubmed: 33360039 doi: 10.1016/j.seizure.2020.12.009
Giovannini, G. et al. Serum neurofilament light as biomarker of seizure-related neuronal injury in status epilepticus. Epilepsia 63, e23–e29 (2022).
pubmed: 34806176 doi: 10.1111/epi.17132
Ouédraogo, O. et al. Increased frequency of proinflammatory CD4 T cells and pathological levels of serum neurofilament light chain in adult drug-resistant epilepsy. Epilepsia 62, 176–189 (2021).
pubmed: 33140401 doi: 10.1111/epi.16742
Nissen, M. S. et al. CSF-neurofilament light chain levels in NMDAR and LGI1 encephalitis: a national cohort study. Front. Immunol. 12, 719432 (2021).
pubmed: 34975832 pmcid: 8716734 doi: 10.3389/fimmu.2021.719432
Lardeux, P. et al. Core cerebrospinal fluid biomarker profile in anti-LGI1 encephalitis. J. Neurol. 269, 377–388 (2022).
pubmed: 34104991 doi: 10.1007/s00415-021-10642-2
Guasp, M. et al. Neurofilament light chain levels in anti-NMDAR encephalitis and primary psychiatric psychosis. Neurology 98, e1489–e1498 (2022).
pubmed: 35145006 doi: 10.1212/WNL.0000000000200021
Ziemssen, T. et al. Serum neurofilament light chain as a biomarker of brain injury in Wilson’s disease: clinical and neuroradiological correlations. Mov. Disord. 37, 1074–1079 (2022).
pubmed: 35114010 doi: 10.1002/mds.28946
Hermann, P. et al. Plasma neurofilament light chain as a biomarker for fatal familial insomnia. Eur. J. Neurol. 29, 1841–1846 (2022).
pubmed: 35212083 doi: 10.1111/ene.15302
Alagaratnam, J. et al. Correlation between cerebrospinal fluid and plasma neurofilament light protein in treated HIV infection: results from the COBRA study. J. Neurovirol. 28, 54–63 (2022).
pubmed: 34874540 doi: 10.1007/s13365-021-01026-3
Smeele, P. J. et al. Neurofilament light increases over time in severe COVID-19 and is associated with delirium. Brain Commun. 4, fcac195 (2022).
pubmed: 35938070 pmcid: 9351727 doi: 10.1093/braincomms/fcac195
Cooper, J. et al. Quantification of neurological blood-based biomarkers in critically ill patients with coronavirus disease 2019. Crit. Care Explor. 2, e0238 (2020).
pubmed: 33063038 pmcid: 7535554 doi: 10.1097/CCE.0000000000000238
Masvekar, R. R. et al. Prognostic value of serum/plasma neurofilament light chain for COVID-19-associated mortality. Ann. Clin. Transl. Neurol. 9, 622–632 (2022).
pubmed: 35313387 pmcid: 9082006 doi: 10.1002/acn3.51542
Abdelhak, A. et al. Prognostic performance of blood neurofilament light chain protein in hospitalized COVID-19 patients without major central nervous system manifestations: an individual participant data meta-analysis. J. Neurol. 270, 3315–3328 (2023).
pubmed: 37184659 pmcid: 10183689 doi: 10.1007/s00415-023-11768-1
Syrjanen, J. A. et al. Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimers Dement. 18, 1128–1140 (2022).
pubmed: 34569696 doi: 10.1002/alz.12466
Bittner, S., Oh, J., Havrdová, E. K., Tintoré, M. & Zipp, F. The potential of serum neurofilament as biomarker for multiple sclerosis. Brain 144, 2954–2963 (2021).
pubmed: 34180982 pmcid: 8634125 doi: 10.1093/brain/awab241
UniProt. P07197 HFM_Human https://www.uniprot.org/uniprotkb/P07197/entry (2024).
UniProt. P12036 NFH_Human https://www.uniprot.org/uniprotkb/P12036/entry (2024).
UniProt. P07196. NFL_Human https://www.uniprot.org/uniprotkb/P07196/entry (2024).
UniProt. Q16352. AINX_Human https://www.uniprot.org/uniprotkb/Q16352/entry (2024).
UniProt. P41219. PERI_Human https://www.uniprot.org/uniprotkb/P41219/entry (2024).

Auteurs

Michael Khalil (M)

Department of Neurology, Medical University of Graz, Graz, Austria. michael.khalil@medunigraz.at.
ORCID: 0000-0002-5350-3328

Charlotte E Teunissen (CE)

Neurochemistry Laboratory Department of Laboratory Medicine, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, Netherlands.

Sylvain Lehmann (S)

LBPC-PPC, Université de Montpellier, INM INSERM, IRMB CHU de Montpellier, Montpellier, France.
ORCID: 0000-0001-6117-562X

Markus Otto (M)

Department of Neurology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
ORCID: 0000-0003-4273-4267

Fredrik Piehl (F)

Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
ORCID: 0000-0001-8329-5219

Tjalf Ziemssen (T)

Center of Clinical Neuroscience, Department of Neurology, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.

Stefan Bittner (S)

Department of Neurology, Focus Program Translational Neuroscience (FTN), and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
ORCID: 0000-0003-2179-3655

Maria Pia Sormani (MP)

Department of Health Sciences, University of Genova, Genova, Italy.
IRCCS Ospedale Policlinico San Martino, Genova, Italy.
ORCID: 0000-0001-6892-104X

Thomas Gattringer (T)

Department of Neurology, Medical University of Graz, Graz, Austria.
Division of Neuroradiology, Vascular and Interventional Radiology, Department of Radiology, Medical University of Graz, Graz, Austria.
ORCID: 0000-0002-6065-6576

Samir Abu-Rumeileh (S)

Department of Neurology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
ORCID: 0000-0003-0631-8506

Simon Thebault (S)

Multiple Sclerosis Division, Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Ahmed Abdelhak (A)

Weill Institute for Neurosciences, Department of Neurology, University of California at San Francisco, San Francisco, CA, USA.
ORCID: 0000-0001-9731-4169

Ari Green (A)

Weill Institute for Neurosciences, Department of Neurology, University of California at San Francisco, San Francisco, CA, USA.

Pascal Benkert (P)

Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
Department of Neurology, University Hospital and University of Basel, Basel, Switzerland.
ORCID: 0000-0001-6525-8174

Ludwig Kappos (L)

Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
Department of Neurology, University Hospital and University of Basel, Basel, Switzerland.

Manuel Comabella (M)

Neurology Department, Multiple Sclerosis Centre of Catalonia, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

Hayrettin Tumani (H)

Department of Neurology, CSF Laboratory, Ulm University Hospital, Ulm, Germany.
ORCID: 0000-0002-1647-6201

Mark S Freedman (MS)

Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

Axel Petzold (A)

Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Neurology, MS Centre and Neuro-ophthalmology Expertise Centre Amsterdam, Amsterdam Neuroscience, Amsterdam, Netherlands.
Moorfields Eye Hospital, The National Hospital for Neurology and Neurosurgery and the Queen Square Institute of Neurology, UCL, London, UK.
ORCID: 0000-0002-0344-9749

Kaj Blennow (K)

Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France.
Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on Aging and Brain Disorders, University of Science and Technology of China and First Affiliated Hospital of USTC, Hefei, P. R. China.
ORCID: 0000-0002-1890-4193

Henrik Zetterberg (H)

Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
UK Dementia Research Institute at UCL, London, UK.
Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.
Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.
ORCID: 0000-0003-3930-4354

David Leppert (D)

Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
Department of Neurology, University Hospital and University of Basel, Basel, Switzerland.

Jens Kuhle (J)

Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland. Jens.Kuhle@usb.ch.
Department of Neurology, University Hospital and University of Basel, Basel, Switzerland. Jens.Kuhle@usb.ch.
ORCID: 0000-0002-6963-8892

Classifications MeSH